Holmium laser enucleation of the prostate versus transurethral resection of the prostate in treatment of benign prostatic hyperplasia: A meta-analysis of 13 randomized control trials

Abstract

Background: The prevalence of benign prostatic hyperplasia (BPH) in older men increases with age, beginning at 40-45 years and reaching to 60% by 60 years and 80% by 80 years. Surgical procedures such as holmium laser enucleation of the prostate (HoLEP) and transurethral resection of the prostate (TURP) are the preferred treatments for BPH. Nevertheless, there is disagreement regarding the most efficient and safe treatment for BPH. The objective of this meta-analysis was to assess the efficacy and safety of HoLEP and TURP based on existing evidence.

Materials and methods: This meta-analysis was performed in accordance with the PRISMA guidelines. In February 2023, a literature review was conducted using PubMed, ScienceDirect, and the Cochrane Library, and the meta-analysis was performed using RevMan V.5.4.

Results: A total of 656 patients underwent HoLEP, and 653 patients underwent TURP. There was no statistically significant difference in the International Prostate Symptom Score at 1 month or at 3, 6, 18, 24, and 36 months; the HoLEP group showed a significant difference at 12 months. The pooled data from the maximum urinary flow rate at 1-12 months revealed no significant findings, but the TURP group showed significant results at 24 months. Meanwhile, the HoLEP group showed significant postvoid residual results. There was no significant difference in the quality of life between the groups. Patients who underwent HoLEP had shorter hospital stay and catheter usage period and had lower hemoglobin drop. The operating time was shorter in the TURP group. The difference in specimen weight between the 2 groups was not statistically significant. The overall complications were similar in both groups, but the HoLEP group received significantly fewer blood transfusions.

Conclusions: Holmium laser enucleation of the prostate demonstrated excellent efficacy and safety, with fewer hematological changes and complications; however, TURP had a shorter operating time.

Keywords

Benign prostatic hyperplasia / Holmium laser enucleation of the prostate / Transurethral resection of the prostate

Acknowledgments

None.

Statement of ethics

This meta-analysis was performed in accordance with the PRISMA guidelines and registered in PROSPRO platform (registry number: CRD42024544803).

Conflict of interest statement

The authors declare no conflicts of interest.

Funding source

None.

Author contributions

BD: Conceived and designed the analysis, collected the data, contributed data or analysis tools, performed the analysis, wrote the paper;

WSS: Collected the data, contributed data or analysis tools, performed the analysis, rote the paper;

PYPP: Performed the analysis, wrote the paper.

Data Availability

The datasets generated during and/or analyzed during the current study are not publicly available, but are available from the corresponding author on reasonable request.

References

[1] Lerner LB, McVary KT, Barry MJ, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA GUIDELINE PART I-Initial work-up and medical management. J Urol 2021; 206(4):806-817.

[2] Bhojani N, Bidair M, Zorn KC, et al. Aquablation for benign prostatic hyperplasia in large prostates (80-150 cc): 1-year results. Urology 2019;129:1-7.

[3] Chung ASJ, Woo HH. Update on minimally invasive surgery and benign prostatic hyperplasia. Asian J Urol 2018; 5(1):22-27.

[4] Wang JW, Man LB. Transurethral resection of the prostate stricture management. Asian J Androl 2020; 22(2):140-144.

[5] Razzaghi MR, Mazloomfard MM, Mokhtarpour H, Moeini A. Diode laser (980 nm) vaporization in comparison with transurethral resection of the prostate for benign prostatic hyperplasia: Randomized clinical trial with 2-year follow-up. Urology 2014; 84(3):526-532.

[6] Gilling PJ, Cass CB, Malcolm AR, Fraundorfer MR. Combination holmium and Nd:YAG laser ablation of the prostate: Initial clinical experience. J Endourol 1995; 9(2):151-153.

[7] Herrmann TR, Bach T, Imkamp F, et al. Thulium laser enucleation of the prostate (ThuLEP): Transurethral anatomical prostatectomy with laser support. Introduction of a novel technique for the treatment of benign prostatic obstruction. World J Urol 2010; 28(1):45-51.

[8] Kyriazis I, Świniarski PP, Jutzi S, et al. Transurethral anatomical enucleation of the prostate with Tm:YAG support (ThuLEP): Review of the literature on a novel surgical approach in the management of benign prostatic enlargement. World J Urol 2015; 33(4):525-530.

[9] Handoyo DB, Soebhali B, Prasetyawan W, Putra PY. Comparison laser anatomical endoscopic enucleation of the prostate (LAEEP) and transurethral resection of the prostate (TURP) in BPH treatment: A meta-analysis. Urine 2022; 4(2022):15-24.

[10] Barboza LE, Malafaia O, Slongo LE, et al. Holmium laser enucleation of the prostate (HoLEP) versus transurethral resection of the prostate (TURP) [in English, Portuguese]. Rev Col Bras Cir 2015; 42(3):165-170.

[11] Shvero A, Calio B, Humphreys MR, Das AK. HoLEP: The new gold standard for surgical treatment of benign prostatic hyperplasia. Can J Urol 2021; 28(S2):6-10.

[12] Zhong J, Feng Z, Peng Y, Liang H. A systematic review and meta-analysis of efficacy and safety following holmium laser enucleation of prostate and transurethral resection of prostate for benign prostatic hyperplasia. Urology 2019;131:14-20.

[13] Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med 2009; 6(7):e1000097.

[14] Phillips B, Ball C, Sackett D, et al. Oxford Centre for evidence-based medicine—Levels of evidence. 2009. Centre for Evidence-Based Medicine web site. Available at: http://www.cebm.net/oxfordcentre-evidence-based-medicine-levels-evidence-march. Accessed March 4, 2019.

[15] Ahyai SA, Lehrich K, Kuntz RM. Holmium laser enucleation versus transurethral resection of the prostate: 3-year follow-up results of a randomized clinical trial. Eur Urol 2007; 52(5):1456-1463.

[16] Bai F, Feng S, Xu C, Xu Z, Chen J, Zheng Y. Transurethral resection versus holmium laser enucleation of the prostate: A prospective randomized trial comparing perioperative thrombin generation and fibrinolysis. Medicine (Baltimore) 2019; 98(15):e15223.

[17] Basić D, Stanković J, Potić M, Ignjatović I, Stojković I. Holmium laser enucleation versus transurethral resection of the prostate: A comparison of clinical results. Acta Chir Iugosl 2013; 60(1):15-20.

[18] Eltabey MA, Sherif H, Hussein AA. Holmium laser enucleation versus transurethral resection of the prostate. Can J Urol 2010; 17(6):5447-5452.

[19] Gilling PJ, Wilson LC, King CJ, Westenberg AM, Frampton CM, Fraundorfer MR. Long-term results of a randomized trial comparing holmium laser enucleation of the prostate and transurethral resection of the prostate: Results at 7 years. BJU Int 2012; 109(3):408-411.

[20] Gupta N, Sivaramakrishna, Kumar R, Dogra PN, Seth A. Comparison of standard transurethral resection, transurethral vapour resection and holmium laser enucleation of the prostate for managing benign prostatic hyperplasia of >40 g. BJU Int 2006; 97(1):85-89.

[21] Hamouda A, Morsi G, Habib E, Hamouda H, Emam AB, Etafy M. A comparative study between holmium laser enucleation of the prostate and transurethral resection of the prostate: 12-month follow-up. J Clin Urol 2014; 7(2):99-104.

[22] Jhanwar A, Sinha RJ, Bansal A, Prakash G, Singh K, Singh V. Outcomes of transurethral resection and holmium laser enucleation in more than 60 g of prostate: A prospective randomized study. Urol Ann 2017; 9(1):45-50.

[23] Kuntz RM, Ahyai S, Lehrich K, Fayad A. Transurethral holmium laser enucleation of the prostate versus transurethral electrocautery resection of the prostate: A randomized prospective trial in 200 patients. J Urol 2004; 172(3):1012-1016.

[24] Mavuduru RM, Mandal AK, Singh SK, et al. Comparison of HoLEP and TURP in terms of efficacy in the early postoperative period and perioperative morbidity. Urol Int 2009; 82(2):130-135.

[25] Montorsi F, Naspro R, Salonia A, et al. Holmium laser enucleation versus transurethral resection of the prostate: Results from a 2-center, prospective, randomized trial in patients with obstructive benign prostatic hyperplasia. J Urol 2004; 172(5 Pt1):1926-1929.

[26] Sayed S, Elshorbagy A, Mahmoud MA, Mostafa D. Holmium laser enucleation of the prostate vs monopolar transurethral resection of the prostate in management of benign prostatic hyperplasia. Egypt J Surg 2021; 40(1):121-130.

[27] Sun N, Fu Y, Tian T, et al. Holmium laser enucleation of the prostate versus transurethral resection of the prostate: A randomized clinical trial. Int Urol Nephrol 2014; 46(7):1277-1282.

[28] Li S, Zeng XT, Ruan XL, et al. Holmium laser enucleation versus transurethral resection in patients with benign prostate hyperplasia: An updated systematic review with meta-analysis and trial sequential analysis. PLoS One 2014; 9(7):e101615.

[29] Gu M, Chen YB, Liu C, et al. Comparison of holmium laser enucleation and plasmakinetic resection of prostate: A randomized trial with 72-month follow-up. J Endourol 2018; 32(2):139-143.

[30] Tan AH, Gilling PJ, Kennett KM, Frampton C, Westenberg AM, Fraundorfer MR. A randomized trial comparing holmium laser enucleation of the prostate with transurethral resection of the prostate for the treatment of bladder outlet obstruction secondary to benign prostatic hyperplasia in large glands (40 to 200 grams). J Urol 2003; 170(4 Pt1):1270-1274.

[31] Michalak J, Tzou D, Funk J. HoLEP: The gold standard for the surgical management of BPH in the 21(st) century. Am J Clin Exp Urol 2015; 3(1):36-42.

[32] Elzayat E, Habib E, Elhilali M. Holmium laser enucleation of the prostate in patients on anticoagulant therapy or with bleeding disorders. J Urol 2006; 175(4):1428-1432.